Skip to main content
Sign In
 

Trialnet: Effect of CTLA-4 Ig (Abatacept) on the Progression of Type 1 Diabetes in New Onset Subject


 

Principal Investigator: Peter Gottlieb, COMIRB #: 07-1213

The CTLA-4 Ig Research Study is looking for people newly diagnosed with type 1 diabetes. 

This research study will use the medication CTLA-4 Ig (Abatacept) to see if we can change the immune system to maintain the body’s ability to produce some insulin.

Why should you consider this study?

  1. When you are first diagnosed with Type 1 Diabetes you still make some insulin.
  2. Over time, your body will lose the ability to make this insulin.
  3. This study will use a medication to try to keep your body making its own insulin.
  4. While your body continues to make its own insulin, your diabetes will be easier to control.
  5. Continued production of some insulin can decrease the risk for long term complications of type 1 diabetes.

Who can sign up for this study?

  1. People recently diagnosed with Type 1 Diabetes within the past 3 months.
  2. 6 years old - 45 years old.

What will happen in this study?

  1. You will be assessed for general health and diabetes care.
  2. If you qualify, you will receive treatment with study medication or fake medication once per month for 2 years.
  3. You will be monitored for 2 additional years to look at your overall diabetes health.

Who should I call with questions or to schedule an appointment?

Jenna Lungaro: 303.724.6758 or Jenna.Lungaro@ucdenver.edu
Lisa Meyers: 303.724.6893 or Lisa.Meyers@ucdenver.edu

TrialNet website: http://www.diabetestrialnet.org